1. Home
  2. ABCL vs PRAX Comparison

ABCL vs PRAX Comparison

Compare ABCL & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABCL
  • PRAX
  • Stock Information
  • Founded
  • ABCL 2012
  • PRAX 2015
  • Country
  • ABCL Canada
  • PRAX United States
  • Employees
  • ABCL N/A
  • PRAX N/A
  • Industry
  • ABCL Biotechnology: Pharmaceutical Preparations
  • PRAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ABCL Health Care
  • PRAX Health Care
  • Exchange
  • ABCL Nasdaq
  • PRAX Nasdaq
  • Market Cap
  • ABCL 1.1B
  • PRAX 950.8M
  • IPO Year
  • ABCL 2020
  • PRAX 2020
  • Fundamental
  • Price
  • ABCL $4.55
  • PRAX $38.46
  • Analyst Decision
  • ABCL Strong Buy
  • PRAX Strong Buy
  • Analyst Count
  • ABCL 5
  • PRAX 9
  • Target Price
  • ABCL $8.00
  • PRAX $94.44
  • AVG Volume (30 Days)
  • ABCL 4.1M
  • PRAX 402.3K
  • Earning Date
  • ABCL 11-03-2025
  • PRAX 11-05-2025
  • Dividend Yield
  • ABCL N/A
  • PRAX N/A
  • EPS Growth
  • ABCL N/A
  • PRAX N/A
  • EPS
  • ABCL N/A
  • PRAX N/A
  • Revenue
  • ABCL $32,875,999.00
  • PRAX $7,765,000.00
  • Revenue This Year
  • ABCL $15.60
  • PRAX N/A
  • Revenue Next Year
  • ABCL $65.70
  • PRAX $25.00
  • P/E Ratio
  • ABCL N/A
  • PRAX N/A
  • Revenue Growth
  • ABCL N/A
  • PRAX 338.45
  • 52 Week Low
  • ABCL $1.89
  • PRAX $26.70
  • 52 Week High
  • ABCL $5.82
  • PRAX $91.83
  • Technical
  • Relative Strength Index (RSI)
  • ABCL 57.55
  • PRAX 30.22
  • Support Level
  • ABCL $4.09
  • PRAX $37.19
  • Resistance Level
  • ABCL $4.28
  • PRAX $40.69
  • Average True Range (ATR)
  • ABCL 0.24
  • PRAX 2.29
  • MACD
  • ABCL 0.03
  • PRAX -0.72
  • Stochastic Oscillator
  • ABCL 82.76
  • PRAX 10.75

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Share on Social Networks: